Emcure Pharmaceuticals Limited is an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
They are a research and development (“R&D”) driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled them to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada. They were ranked as (i) the 13th largest pharmaceutical company in India in terms of Domestic Sales for MAT Financial Year 2024, (ii) the 4th largest pharmaceutical company by market share in their Covered Markets in terms of Domestic Sales for MAT Financial Year 2024, and (iii) the largest pharmaceutical company in the gynecology and human immunodeficiency virus (“HIV”) antivirals therapeutic areas in India in terms of Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report).
Their competitive advantage in the domestic market stems from their differentiated product portfolio, which has allowed them to establish their presence in most of the major therapeutic areas, including gynecology, cardiovascular, vitamins, minerals and nutrients, HIV antivirals, blood-related and oncology/anti-neoplastics. Across the gynecology, vitamins, minerals and nutrients, HIV antivirals, blood-related and oncology/antineoplastics therapeutic areas, they were ranked among the 10 largest pharmaceutical companies in India in terms of Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report).
They have demonstrated strong capabilities and a proven track record in building brands. Six of their brands were ranked among the 300 highest selling brands in the IPM, in terms of Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report). They had 26 brands with Domestic Sales of over ₹500.00 million for MAT Financial Year 2024, as compared to 13 brands for MAT Financial Year 2020 (Source: CRISIL Report). In addition, 16 of their top 20 brands were each ranked among the three highest selling brands in their respective therapeutic areas in the IPM, in terms of Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report).
Note: The actual amount will be debited when the shares are allotted to you.
Note: The actual amount will be debited when the shares are allotted to you.
An IPO offers share market participants like you and me an opportunity to be a shareholder in an erstwhile privately held company that is now going public and being listed on the market. Historically speaking, investors who choose the right IPOs make significant returns on their investments, which increases the attraction of IPOs.
Once you are a shareholder, you are eligible to receive dividends from the company proportional to the shares you own. You can also sell your stocks for profit on the stock exchange.
In exchange for its shares, the company has an opportunity to raise huge capital to be used to further enhance its business and scale up its operations. The company also has other benefits, such as credibility; visibility; better leverage to effect mergers, acquisitions and even to procure loans at lower rates of interest.
In India, the entire IPO process is ably regulated by the Securities & Exchange Board of India (SEBI), right from the IPO filing by the company to the bidding, allotments and refunds (in case you aren't allotted shares due to oversubscription).
Yes. IPO & Bonds will reflect in the portfolio.
In case the allotment is not done then bank will unblock the application money from the bank accounts upon receiving instructions from the Registrar.
Bidding time will be till 1200 hrs on the closing day of the issue.
Your bank should be a part of the ASBA participating bankers. Click here to check the list of banks.
Yes, you will receive a sms once the IPO form is processed.
BSE IPO index to track the value of companies for two years after listing subsequent to successful completion of their initial public offering (IPO).
This report provides the debit/credit entry of all the transfers done in the IPO and MF account
Click here to check the status of your IPO application
This product is a Loan Facility offered for applying in Primary Market Issues (IPOs and FPOs). With this product Investors can apply for IPOs by investing only Margin amount (specified for each IPO separately).
